Free Trial

Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis

Milestone Pharmaceuticals logo
$1.42 -0.02 (-1.39%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$1.43 +0.01 (+0.70%)
As of 05/29/2026 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Milestone Pharmaceuticals Stock (NASDAQ:MIST)

Advanced

Key Stats

Today's Range
$1.41
$1.46
50-Day Range
$1.01
$2.20
52-Week Range
$1.00
$3.06
Volume
518,422 shs
Average Volume
1.48 million shs
Market Capitalization
$176.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25
Consensus Rating
Moderate Buy

Company Overview

Milestone Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

MIST MarketRank™: 

Milestone Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 412th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Milestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    Milestone Pharmaceuticals has a consensus price target of $7.25, representing about 410.6% upside from its current price of $1.42.

  • Amount of Analyst Coverage

    Milestone Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Milestone Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.97) to ($1.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Milestone Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Milestone Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Milestone Pharmaceuticals has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Milestone Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.47% of the float of Milestone Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 4.27.
  • Change versus previous month

    Short interest in Milestone Pharmaceuticals has recently decreased by 4.17%, indicating that investor sentiment is improving.
  • Dividend Yield

    Milestone Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Milestone Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Milestone Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Milestone Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for MIST on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Milestone Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,490.00 in company stock.

  • Percentage Held by Insiders

    19.50% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Milestone Pharmaceuticals' insider trading history.
Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MIST Stock News Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Headlines

MIST Stock Analysis - Frequently Asked Questions

Milestone Pharmaceuticals' stock was trading at $2.02 at the beginning of the year. Since then, MIST shares have decreased by 29.7% and is now trading at $1.42.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its earnings results on Wednesday, May, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.26. The firm earned $0.24 million during the quarter, compared to analyst estimates of $30.12 million.
Read the conference call transcript
.

Milestone Pharmaceuticals (MIST) raised $82 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Top institutional shareholders of Milestone Pharmaceuticals include Renaissance Technologies LLC (0.11%), SG Americas Securities LLC (0.04%) and Welch & Forbes LLC (0.02%). Insiders that own company stock include Joseph Oliveto, Lorenz Muller, David Bharucha and Jeffrey Edward Nelson.
View institutional ownership trends
.

Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), Aquestive Therapeutics (AQST).

Company Calendar

Last Earnings
5/13/2026
Today
5/31/2026
Next Earnings (Estimated)
8/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MIST
CIK
1408443
Fax
N/A
Employees
30
Year Founded
2005

Price Target and Rating

High Price Target
$8.00
Low Price Target
$6.00
Potential Upside/Downside
+410.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.06 million
Net Margins
N/A
Pretax Margin
-3,933.43%
Return on Equity
-339.33%
Return on Assets
-61.79%

Debt

Debt-to-Equity Ratio
1.61
Current Ratio
9.18
Quick Ratio
9.09

Sales & Book Value

Annual Sales
$1.55 million
Price / Sales
114.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
4.90

Miscellaneous

Outstanding Shares
124,500,000
Free Float
100,221,000
Market Cap
$176.79 million
Optionable
Optionable
Beta
1.04

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:MIST) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners